Boston trumps Johnson & Johnson bid again with $27bn offer for Guidant
This article was originally published in Clinica
Boston Scientific has hiked its offer for Guidant by nearly $2bn, proposing to pay $27bn for the cardiology firm. The last few days have seen the tug-of-war between Boston and Johnson & Johnson for Guidant intensify with a series of bids and counterbids. The latest volley served by Boston Scientific trumps J&J's most recent bid of $24.2bn, which it made late on Friday (January 13).